Sulthiame Shows Promise as New Drug for Sleep Apnea | The Lancet Study

For years, the primary treatment for obstructive sleep apnea (OSA) has been continuous positive airway pressure, or CPAP, therapy – a machine that delivers a steady stream of air through a mask to keep airways open during sleep. But CPAP isn’t a perfect solution. Many find the mask uncomfortable, disruptive, or simply can’t tolerate it, leading up to half of users to discontinue treatment within a year. Now, a European clinical trial offers a potential new avenue for relief: a medication called sulthiame. The findings, published in The Lancet, suggest that sulthiame could reduce breathing pauses and improve sleep quality for those struggling with moderate to severe OSA.

Understanding Obstructive Sleep Apnea

Obstructive sleep apnea occurs when the muscles in the back of the throat relax during sleep, causing the upper airway to repeatedly collapse. These pauses in breathing, known as apneas, lead to reduced oxygen levels and fragmented sleep. Untreated OSA isn’t just about daytime fatigue; it’s linked to a range of serious health problems, including high blood pressure, cardiovascular disease, stroke and type 2 diabetes. The condition is surprisingly common, affecting millions worldwide, though precise prevalence figures vary depending on diagnostic criteria and population studied.

How Sulthiame Works: Stabilizing Breathing Control

Sulthiame, already approved for treating certain types of childhood epilepsy, appears to work by stabilizing the body’s breathing control and increasing what’s known as respiratory drive. Essentially, it helps prevent the upper airway from collapsing during sleep. Researchers believe it achieves this by inhibiting carbonic anhydrase, an enzyme involved in regulating breathing. A study published in PubMed details the mechanism and trial design, noting that sulthiame improves both ventilatory response and upper airway muscle activity.

The European Clinical Trial: A Closer Look

The recent trial involved 298 patients with moderate to severe OSA across four European countries. Participants were randomly assigned to receive either a placebo or varying doses of sulthiame. Crucially, the study was “double-blind,” meaning neither the patients nor the researchers knew who was receiving the active drug. This design minimizes bias and strengthens the reliability of the results. The primary outcome measured was the change in the Apnoea-Hypopnea Index (AHI), a score that quantifies the number of breathing interruptions per hour of sleep.

The results were promising. Patients receiving higher doses of sulthiame experienced up to a 47 percent reduction in breathing interruptions compared to those on the placebo. They also showed improved oxygenation levels overnight. According to Jan Hedner, senior professor of pulmonary medicine at the Sahlgrenska Academy, University of Gothenburg, and a leading researcher on the study, “It feels like a breakthrough, and we now look forward to larger and longer studies to determine whether the effect is sustained over time and whether the treatment is safe for broader patient groups.”

Safety and Side Effects: What the Trial Revealed

While the results are encouraging, it’s important to note that sulthiame isn’t without potential side effects. The trial reported that most side effects were mild and temporary. However, an earlier, smaller study, published in PubMed in 2022, noted that intermittent paresthesia (tingling sensations) was reported by a significant percentage of patients receiving higher doses of sulthiame (up to 79% in the 400mg group). Dyspnea, or shortness of breath, was also reported in some cases. Six patients in the higher dose group withdrew from that earlier trial due to adverse events, though no serious adverse events were reported.

Limitations and What the Research Doesn’t Tell Us

It’s crucial to understand the limitations of this research. The trial focused on patients with moderate to severe OSA. The effectiveness of sulthiame in individuals with milder forms of the condition remains unknown. The study duration was relatively short (15 weeks). Long-term effects and the sustainability of the observed benefits require further investigation. The trial also primarily included participants of European descent; the results may not be generalizable to other populations.

The study also doesn’t address the optimal duration of treatment or the potential for tolerance to develop over time. It’s also important to remember that correlation doesn’t equal causation. While the study demonstrates an association between sulthiame and reduced breathing interruptions, it doesn’t definitively prove that the drug *causes* this improvement. Other factors could be at play.

What’s Next: Larger Trials and Broader Evaluation

The University of Gothenburg researchers are planning larger and longer-term studies to address these questions. These future trials will aim to confirm the sustained efficacy and safety of sulthiame in a more diverse patient population. Researchers will also investigate the optimal dosage and duration of treatment. The ultimate goal is to determine whether sulthiame can turn into a viable, drug-based treatment option for individuals with OSA who cannot tolerate or benefit from CPAP therapy. The process of bringing a new drug to market is lengthy and rigorous, involving multiple phases of clinical trials and regulatory review.

For now, individuals concerned about sleep apnea should consult with a qualified healthcare professional for diagnosis and treatment options. CPAP remains the gold standard therapy, and lifestyle modifications, such as weight loss and avoiding alcohol before bed, can also play a role in managing the condition. Staying informed about ongoing research and discussing treatment options with your doctor is the best course of action.